Editor Profile
Dr. Qi Wang, Ph.D.
Postdoctoral Clinical Pharmacologist
Present
A2-Ai LLC, Ann Arbor, Michigan
Ann Arbor, MI 48104
United States
Dr. Qi Wang is a highly skilled and accomplished clinical pharmacologist and pharmaceutical scientist with extensive expertise in drug delivery systems, pharmacokinetics and clinical pharmacology. Currently working as a Postdoctoral Clinical Pharmacologist at A2-Ai LLC in Ann Arbor, MI, Dr. Wang supports Investigational New Drug (IND) and New Drug Application (NDA) submissions. Her work includes evaluating drug-drug interactions and conducting non-compartmental analyses to ensure the safety and efficacy of therapeutic regimens.
Prior to her current role, Dr. Wang was an ORISE Fellow at the U.S. FDA in Silver Spring, MD, where she contributed to the development of assessment metrics for complex drug products. She collaborated with cross-functional teams to address bioequivalence challenges and contributed to developing FDA product-specific guidance for generic drug development in areas such as respiratory diseases and pain management.
Dr. Wang earned her Ph.D. in Pharmaceutics from Auburn University, where her research focused on the development of micelle delivery systems for cancer therapy. Her innovative work included designing drug-copper chelated nanoparticles that significantly enhanced therapeutic efficacy. During her graduate studies, she published multiple papers in leading biomedical journals and presented her findings at international conferences, including the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360.
Before her Ph.D., Dr. Wang completed her M.Sc. in Pharmaceutics at Shenyang Pharmaceutical University in China, where she specialized in pH/redox dual-responsive polymeric micelles for gene and drug co-delivery. Her research demonstrated strong tumor inhibition and gene silencing efficacy in preclinical models, contributing to advanced cancer therapies.
With a strong publication record and a commitment to advancing pharmaceutical science, Dr. Qi Wang continues to make significant contributions to drug development and regulatory science, bridging the gap between preclinical research and clinical applications.
- Formulation
- Drug Delivery
- Gene Delivery
- Pharmaceutics
- Nanoparticles
- Pharmacokinetics
- Biopharmaceutics
- Clinical Pharmacology
- Wang, Q., Tiwari, A.K., Li, F., Babu, R. Jayachandra. An Up-to-Date Review of Elesclomol and Its Nano-Formulations in Cancer Therapy. Cancer Reports. 2024.
- Wang, Q., Huang, C., Li, F., Babu, R. Jayachandra. Codelivery of ROS Triggered Release Disulfiram Prodrug and Copper for Cancer Therapy. (In preparation).
- Wang, Q., Mita, N., Babu, R. Jayachandra. 3D Printed Oral Fast Dissolving Films for Targeted Patients with Parkinson’s Disease. (In preparation).
- Wang, Q., Huang, C. H., Wibowo, F. S., Amin, R., Shen, J., Li, F., Babu, R. J. Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells. ACS Appl Mater Interfaces. 2024.
- Jia, N., Wang, Q., Li, W., Chen, D., Hu, H. Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment. Adv. Healthcare Mater. 2024.
- Annaji, M., Mita, N., Poudel, I., Wang, Q., … Lyman, C. Inclusion Complex of Clomiphene Citrate with Hydroxypropyl-β-Cyclodextrin for Intravenous Injection: Formulation and Stability Studies. AAPS PharmSciTech. 2023.
- Kang, X., Wang, Q., … Babu, R.J. Liposomal DQ in Combination with Copper Inhibits ARID1A Mutant Ovarian Cancer Growth. Biomolecules. 2023.
- Wang, Q., Atluri, K., Tiwari, A.K., Babu, R.J. Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine. Pharmaceuticals. 2023.
- Kang, X., Cai, Y., Wang, Q., … Li, F. Near-infrared Light Triggered Activation of Pro-drug Combination Cancer Therapy and Induction of Immunogenic Cell Death. Int J Pharm. 2021.
- Gao, Y., Jia, L., Wang, Q., Hu, H., Zhao, X., Chen, D., Qiao, M. pH/Redox Dual-Responsive Polyplex with Effective Endosomal Escape for Codelivery of siRNA and Doxorubicin against Drug-Resistant Cancer Cells. ACS Appl Mater Interfaces. 2019.
- Zhu, J., Qiao, M., Wang, Q., … Chen, D. Dual-responsive Polyplexes with Enhanced Disassembly and Endosomal Escape for Efficient Delivery of siRNA. Biomaterials. 2018.
- Jia, N., Ye, Y., Wang, Q., Zhao, X., Hu, H., Chen, D., Qiao, M. Preparation and Evaluation of poly(L-Histidine) Based pH Sensitive Micelles for Intracellular Delivery of Doxorubicin against MCF-7/ADR Cells. Asian J. Pharm. Sci. 2017.
